The estimated Net Worth of Shacey Petrovic is at least 23.9 百万$ dollars as of 28 February 2024. Ms. Petrovic owns over 11,609 units of Insulet stock worth over 3,228,300$ and over the last 10 years she sold PODD stock worth over 14,785,101$. In addition, she makes 5,883,980$ as President、 Chief Executive Officer、 Director at Insulet.
Shacey has made over 28 trades of the Insulet stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 11,609 units of PODD stock worth 1,069,305$ on 28 February 2024.
The largest trade she's ever made was selling 35,000 units of Insulet stock on 13 November 2023 worth over 5,762,050$. On average, Shacey trades about 3,614 units every 30 days since 2015. As of 28 February 2024 she still owns at least 14,176 units of Insulet stock.
You can see the complete history of Ms. Petrovic stock trades at the bottom of the page.
Shacey Petrovic serves as President, Chief Executive Officer, Director of the Company. Ms. Petrovic has served as our President and Chief Executive Officer since January 1, 2019 and has served on our Board of Directors since September 2018. From October 2016 to January 2019, Ms. Petrovic served as our President and Chief Operating Officer. From February 2016 to October 2016, Ms. Petrovic served as our Executive Vice President and President, Diabetes Products, and from February 2015 to February 2016, she served as our Chief Commercial Officer. From 2013 to 2015, Ms. Petrovic served as President and Chief Executive Officer of Clinical Innovations, LLC, a developer and manufacturer of medical devices and diagnostics for women’s health. From 2000 to 2013, Ms. Petrovic served in a number of key roles at Hologic, Inc. and Cytyc Corporation, which merged with Hologic in October 2007, including Vice President and General Manager of Hologic’s GYN Surgical Products division, as well as various sales and marketing leadership roles in the U.S. and Europe. Ms. Petrovic earned her Bachelor of Science in Biology from the University of Wisconsin.
As the President、 Chief Executive Officer、 Director of Insulet, the total compensation of Shacey Petrovic at Insulet is 5,883,980$. There are no executives at Insulet getting paid more.
Shacey Petrovic is 47, she's been the President、 Chief Executive Officer、 Director of Insulet since 2019. There are 20 older and 2 younger executives at Insulet. The oldest executive at Insulet Corporation is John Fallon, 72, who is the Independent Director.
Shacey's mailing address filed with the SEC is C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON, WI, 53719.
Over the last 18 years, insiders at Insulet have traded over 64,849,299$ worth of Insulet stock and bought 175,262 units worth 7,280,516$ . The most active insiders traders include Jonathan Silverstein、Elizabeth H Weatherman、Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of 2,473,148$. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth 1,129,200$.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: